Antibe Therapeutics Inc(Pre-Merger) ATBPF

Bloom Burton ... FYI

[MrMugsy]

If you listened to the presentation, you would have heard $8M for CITA.
That isn't the case.
The sale price for CITA was $6.5M ... confirmed.

[Doccole]

Just watched it.  They anticipate a run up going into phase 2.   do we think they will announce Nasdq uplist in the fall? how high at best and worst can we expect our MC going into phase 2?

[MrMugsy]

Oh my Doccole - that's a lot of questions ... I will try to answer the NASDAQ question ... as he did give a little shout-out to the NASDAQ crew on his team.  That's a good thing. The NASDAQ move is likely going to depend on a few things ... first - the share price movement 2nd - the appetite from the US side 3rd - expected ATE advances and drug development Therefore, I wouldn't

[themagicbox]

I hope you are right Mugs. I am leaning towards nothing to the SP or increased interest till september. I am bullish long term though. 

[MrMugsy]

Yes - agreed. There are many unknowns so timing is way up in the air. Removing CITAGENIX, leaves the following mash-up ... IMO 1.  346 acute commercial study expected (Q2) 2.  346 acute regimen optimization and prep work (Q2-Q3) for P2 start (Q4) 3.  FDA applications for fast-track and/or breakthrough therapy and/or other programs 4.  Discovery - IV opportunity 5.  346

[Scotchnoice]

6,5 m$ wich including 3m$ linked to certain milestones so it could be lower than that.

[MrMugsy]

Correct !